Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis

Peter Rossing(Steno Diabetes Centers), Márcio Krakauer, Andrew E. Ajani, G. Levterov, Francis Duyck, Søren Rasmussen(Novo Nordisk (Denmark)), A. Wassermann, Shaobo Tan, Christophe De Block(University of Antwerp), Jean‐Pierre Salles, Kenneth W. Mahaffey(Cardiovascular Institute of the South), C. Vercammen, Katherine R. Tuttle(Providence Regional Medical Center Everett), V. Preumont, Roland E. Schmieder(Universitätsklinikum Erlangen), Z. Nikitov, Daniel Franco, Bilyana Stoyanovska-Elencheva, Richard Phoon, Kerr Pg, Corinne Debroye, Alicia Elbert, Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Roza Bobeva, Zdravko Kamenov(Medical University of Sofia), Luís Henrique Santos Canani(Hospital de Clínicas de Porto Alegre), Heidrun Bosch‐Traberg(University of Copenhagen), Alejandro Chertkoff, Elizabeth Gelersztein, Andrea Da Porto, Gustavo Akerman Augusto, Robert S. Busch(Albany Medical Center Hospital), David Colquhoun, Vlado Perkovic(University of Copenhagen), A. Oviedo, J.M. Krzesinski, Amanda Mather(Royal North Shore Hospital), R. J. MacIsaac, S Roger, Johannes F. E. Mann(Universitätsklinikum Erlangen), Nicolas Belmar(Novo Nordisk (Denmark)), Thomas Idorn(University of Copenhagen), Miguel Ángel Quevedo, S. Gerilovska, Bruno Lapauw, N. Yabrudi, George L. Bakris(Pennsylvania State System of Higher Education)
Diabetes Care
July 29, 2025
Cited by 16


Related Papers